Abstract
Clinical use of the polymyxin antibiotics began approximately 10 years after their discovery in the late 1940s. Their concentrations in biological fluids were measured using microbiological methods. These methods were reasonably accurate for measuring the active polymyxin base, such as polymyxin B and colistin (polymyxin E), but were used inappropriately for measuring the concentrations of “colistin” in humans or animals following the administration of colistimethate, also known as colistin methanesulphonate (CMS). The use of polymyxins for systemic infections waned in the 1970s because of their toxicity and the preference for other antibiotics, but their value for treating infections caused by several important Gram-negative pathogens becoming resistant to other antibiotics was realized in the mid-1990s. The lack of adequate pharmacokinetic and pharmacodynamic knowledge spurred the development of methods more specific for measuring polymyxin B and colistin after their administrations as sulphate salts, and of colistin and CMS after the administration of CMS sodium. These methods have been based on high-performance liquid chromatography, detection and quantification of fluorescent derivatives of the polymyxin bases, or of the bases themselves with detection and quantification by mass spectrometry.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dudhani RV, Nation RL, Li J (2010) Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 65(7):1412–1415
Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW (2001) A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761(2):167–175
Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J (2002) Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46(10):3304–3307
Gobin P, Lemaitre F, Marchand S, Couet W, Olivier JC (2010) Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54(5):1941–1948
Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE (2009) Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 49(3):760–767
Meng M, Wang L, Liu S, Jaber O, Gao L, Chevrette L, Reuschel S (2016) Simultaneous quantitation of polymyxin B1, polymyxin B2 and polymyxin B1-1 in human plasma and treated human urine using solid phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B 1012–1013:23–36
Brownlee G, Bushby SRM, Short EI (1949) The pharmacology of polymyxin A, B, and D. Ann NY Acad Sci 51(5):952–967
Stansly PG (1949) A simple method for the assay of polymyxin in blood and urine. Ann NY Acad Sci 51:980–981
Stansly PG (1948) Studies on polymyxin: an assay method for blood and urine. Proc Soc Exp Biol Med 68:301–304
Craig WA, Kunin CM (1973) Dynamics of binding and release of the polymyxin antibiotics by tissues. J Pharmacol Exp Ther 184(3):757–765
Ziv G, Schultze WD (1982) Pharmacolunetics of polymyxin B administered via the bovine mammary gland. J Vet Pharmacol Ther 5:123–129
Ziv G, Nouws JF, van Ginneken CA (1982) The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 5(1):45–58
Ziv C, Wanner M, Nicolet J (1980) Clinical pharmacology of polymyxin B, colistin and colistimethate in young calves. J Vet Pharmacol Ther 3:87–94
Wootton M, Holt HA, MacGowan AP (2005) Development of a novel assay method for colistin sulphomethate. Clin Microbiol Infect 11:243–244
Bergen PJ, Li J, Rayner CR, Nation RL (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):1953–1958
Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K (2003) Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 47(4):1364–1370
Healy DP, Sombun AD, Gardner JC, Good K, Durkee PJ, Toner L, Rieman MT, Neely AN, Kagan RJ (2011) Pharmacokinetics of colistin in an adolescent boy with extensive burn injury. J Burn Care Res 32(1):e7–e11
Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J (2002) Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21(3):212–214
Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, AIshii Y, Tanabe Y, Gejyo F, Yamaguchi K (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63(3):534–542
Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N (2012) In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 56(5):2683–2690
Lin B, Zhang C, Xiao X (2005) Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 28(4):349–354
Sarria JC, Angulo-Pernett F, Kimbrough RC, McVay CS, Vidal AM (2004) Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis 23:340–341
Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH (1997) Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52:987–993
Hermsen ED, Sullican CJ, Rotschafer JC (2003) Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17:545–562
Le Brun PP, de Graaf AI, Vinks AA (2000) High-performance liquid chromatographic method for the determination of colistin in serum. Ther Drug Monit 22(5):589–593
Decolin D, Leroy P, Nicolas A, Archimbault P (1997) Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 35(12):557–564
Reed MD, Stern RC, O’Riordan MA, Blumer JL (2001) The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41(6):645–654
Guyonnet J, Manco B, Baduel L, Kaltsatos V, Aliabadi MH, Lees P (2010) Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs. Res Vet Sci 88(2):307–314
Gmur DJ, Bredl CR, Steele SJ, Cai S, VanDevanter DR, Nardella PA (2003) Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography. J Chromatogr B 789(2):365–372
Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J (2003) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52(6):987–992
Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K (2004) Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53(5):837–840
Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP (2014) Pulmonary and systemic pharmacokinetics of Inhaled and Intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58(8):2570–2579
Koomanachai P, Landersdorfer CB, Chen G, Lee HJ, Jitmuang A, Wasuwattakul S, Sritippayawan S, Li J, Nation RL, Thamlikitkula V (2014) Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 58(1):440–446
Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284–3294
Dudhani RV, Turnidge J, Coulthard K, Milne R, Rayner CR, Li J, Nation RL (2010) Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54(3):1117–1124
Yapa SWS, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP (2013) Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 57(10):5087–5095
He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts KD, Velkov T, Li J (2013) Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68(10):2311–2317
Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW (2008) Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61(3):636–642
Jin L, Li J, Nation RL, Nicolazzo JA (2009) Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob Agents Chemother 53(10):4247–4251
Jin L, Li J, Nation RL, Nicolazzo JA (2012) Effect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice. Antimicrob Agents Chemother 56(10):5240–5246
Yousef JM, Chen G, Hill PA, Nation RL, Li J (2012) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67(2):452–459
Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55(9):4044–4049
Cao G, Ali F, Chiu F, Alexandre P, Zavascki A, Nation R, Li J (2008) Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 62(5):1009–1014
Ali FE, Cao G, Poudyal A, Vaara T, Nation RL, Vaara M, Li J (2009) Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. J Antimicrob Chemother 64(5):1067–1070
Zavascki AP, Li J, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL (2008) Pharmacokinetics of intravenous polymyxin B in critically-ill patients. Clin Infect Dis 47:1298–1304
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP (2013) Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis 57:524–531
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J (2013) Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 68(3):674–677
Markou N, Markantonis SI, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 30(1):143–151
Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I, Dimopoulou E, Baltopoulos G (2009) Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 53(11):4907–4910
Ziaka M, Markantonis SL, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M, Makris D, Zakynthinos E (2013) Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 57(4):1938–1940
Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 138(6):1333–1339
Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ (2012) Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38(11):1779–1786
Zeng Z, Wu J, Yang G, Chen Z, Huang X, Ding H (2010) Study of colistin depletion in duck tissues after intramuscular and oral administration. J Vet Pharmacol Ther 33(4):408–410
He J, Tang S, Li L, Zhang C, Li X, Xia X, Xiao X (2011) Pharmacokinetics of a novel amoxicillin/colistin suspension after intramuscular administration in pigs. J Vet Pharmacol Ther 34(1):42–50
Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57(2):306–311
Dotsikas Y, Markopoulou CK, Koundourellis JE, Loukas YL (2011) Validation of a novel LC-MS/MS method for the quantitation of colistin A and B in human plasma. J Sep Sci 34(1):37–45
Ma Z, Wang J, Gerber JP, Milne RW (2008) Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 862(1–2):205–212
Sin DW, Ho C, Wong Y, Ho S, Ip AC (2005) Analysis of major components of residual bacitracin and colistin in food samples by liquid chromatography tandem mass spectrometry. Anal Chim Acta 535(1–2):23–31. https://doi.org/10.1016/j.aca.2004.11.063
Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53(8):3430–3436
Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56(8):4241–4249
Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H (2013) Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57(1):668–671
Leporati M, Ornella Bua RO, Mariano F, Carignano P, Stella M, Biancone L, Marco Vincenti M (2014) Determination by LC–MS/MS of Colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 36:182–191
Gikas E, Bazoti FN, Katsimardou M, Anagnostopoulos D, Papanikolaou K, Inglezos I, Skoutelis A, Daikos GL, Tsarbopoulos A (2013) Determination of colistin A and colistin B in human plasma by UPLC–ESI high resolution tandem MS: application to a pharmacokinetic study. J Pharm Biomed Anal 83:228–236
Zhao M, Wu XJ, Fan YX, Guo BN, Zhang J (2016) Development and validation of a UHPLC–MS/MS assay for colistin methanesulphonate (CMS) and colistin in human plasma and urine using weak-cation exchange solid-phase extraction. J Pharm Biomed Anal 124:303–308
Cheng C, Liu S, Xiao D, Hollembaek J, Yao L, Lin J, Hansel S (2010) LC–MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B 878(28):2831–2838
Mercier T, Tissot F, Gardiol C, Corti N, Wehrli S, Guidi M, Csajka C, Buclin T, Couet W, Marchetti O, Decosterd LA (2015, 1369) High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. J Chromatogr A:52–63
Thomas TA, Broun EC, Abildskov KM, Kubin CJ, Horan J, Yin MT, Cremers S (2012) High performance liquid chromatography–mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 34:398–405
Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH (2008) Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 60(2):163–167
Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH (2012) Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56(11):5724–5727
He J, Abdelraouf K, Ledesma KR, Chow DS-L, Tam VH (2013) Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents 42(6):559–564
Tam VH, Cao H, Ledesma KR, Hu M (2011) In vitro potency of various polymyxin B components. Antimicrob Agents Chemother 55(9):4490–4491
He J, Gao S, Hu M, Chow DS-L, Tam VH (2013) A validated ultra-performance liquid chromatography–tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 68:1104–1110
Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL (2008) Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52(9):3047–3051
Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ (2010) Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B Condens Matter Mater Surf Interfaces Biophysical 114(14):4836–4840
Karvanen M (2013) Optimization of colistin dosage in the treatment of multiresistant gram-negative infections. Doctoral thesis, Uppsala Universitet, Uppsala
Cheah S-E, Jurgen B, Bulitta JB, Li J, Nation RL (2014) Development and validation of a liquid chromatography–mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92:177–182
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Milne, R.W. (2019). Bioanalysis and Stability of Polymyxins. In: Li, J., Nation, R., Kaye, K. (eds) Polymyxin Antibiotics: From Laboratory Bench to Bedside. Advances in Experimental Medicine and Biology, vol 1145. Springer, Cham. https://doi.org/10.1007/978-3-030-16373-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-16373-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16371-6
Online ISBN: 978-3-030-16373-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)